Roquefort Therapeutics STAT-6 siRNA Shows Efficacy in Experimental Model, Pursues Out-Licensing Deal

(4:34)

Roquefort Therapeutics CEO Ajan Reginald on 'transformational' sale of Lyramid subsidiary

(3:48)

Roquefort Therapeutics CEO Ajan Reginald discusses MK cell therapy patent and other milestones

(6:49)

Roquefort Therapeutics inks first strategic licensing deal with diagnostics firm Randox

(3:58)

Roquefort Therapeutics making headway with siRNA

(7:33)

Roquefort Therapeutics says new mRNA platform \

(5:2)

Roquefort Therapeutics establishes scientific advisory board

(5:34)

Roquefort Therapeutics demonstrates initial safety in two antibody programmes

(4:26)

Roquefort Therapeutics calls Oncogeni acquisition 'transformational'

(8:3)

Roquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patents

(4:44)

Roquefort Therapeutics returns to the market with new study data

(5:35)

Roquefort Therapeutics portfolio expands to ‘five highly innovative medicines’

(16:49)

Roquefort Therapeutics explains the significance of its \

(2:3)

Roquefort Therapeutics's CEO on how the company tackles cancer

(4:8)

Roquefort Therapeutics CEO lays out strategy for 2023

(7:14)

Roquefort Therapeutics - Developing Innovative Treatments for the Hardest to Treat Cancers #roq

(7:38)

Roquefort Therapeutics plc (OTCQB: ROQAF | LSE: ROQ): Virtual Investor Conferences

(29:57)

Roquefort Therapeutics presents at the Proactive One2One Investor Forum - October 6th 2022

(20:36)

ROQUEFORT THERAPEUTICS PLC - Investor Presentation

(36:24)